Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York. Show more

Location: 1500 Broadway, New York, NY, 10036, United States | Website: https://www.nuvationbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

748.6M

52 Wk Range

$1.54 - $3.97

Previous Close

$2.31

Open

$2.28

Volume

3,355,396

Day Range

$2.17 - $2.31

Enterprise Value

213.2M

Cash

461.7M

Avg Qtr Burn

-39.33M

Insider Ownership

19.14%

Institutional Own.

61.81%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Safusidenib Details
High-grade Glioma

Phase 2

Update

NUV-1511 Details
Advanced solid tumors

Phase 1/2

Data readout

NUV-868 +olaparib Details
Solid tumor/s, Cancer, Ovarian cancer, Pancreatic cancer, Triple-negative breast cancer , Castration-resistant prostate cancer

Phase 1b

Update

NUV-868 +enzalutamide Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Phase 1b

Update

Phase 1

Update

NUV-422 (CDK inhibitor) Details
High-grade Glioma , Solid tumor/s, Cancer, Prostate cancer, Breast cancer, Castration-resistant prostate cancer, Metastatic breast cancer

Failed

Discontinued